Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cells
- 22 June 2007
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 358 (1) , 92-98
- https://doi.org/10.1016/j.bbrc.2007.04.083
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Current Status of Taxane and Platinum-Based Chemotherapy in Ovarian CancerJournal of Clinical Oncology, 2003
- Current clinical practices for ovarian cancersSeminars in Oncology, 2002
- Hypoxia and interleukin-1β stimulate vascular endothelial growth factor production in human proximal tubular cellsKidney International, 2000
- Structure, Recognition, and Processing of Cisplatin−DNA AdductsChemical Reviews, 1999
- Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1Journal of Biological Chemistry, 1996
- Heterozygous embryonic lethality induced by targeted inactivation of the VEGF geneNature, 1996
- Vascular endothelial growth factor, a specific regulator of angiogenesisCurrent Opinion in Nephrology and Hypertension, 1996
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Vascular permeability factor (VPF, VEGF) in tumor biologyCancer and Metastasis Reviews, 1993
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993